BR9809047A - Derivados de isoquinolina substituìda e o uso dos mesmos como anticonvulsivantes - Google Patents

Derivados de isoquinolina substituìda e o uso dos mesmos como anticonvulsivantes

Info

Publication number
BR9809047A
BR9809047A BR9809047-0A BR9809047A BR9809047A BR 9809047 A BR9809047 A BR 9809047A BR 9809047 A BR9809047 A BR 9809047A BR 9809047 A BR9809047 A BR 9809047A
Authority
BR
Brazil
Prior art keywords
alkyl
tetrahydroisoquinolin
cycloalkyl
hydrogen
methoxybenzamide
Prior art date
Application number
BR9809047-0A
Other languages
English (en)
Inventor
Mervyn Thompson
Robert William Ward
Peter David Edwards
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9705619.6A external-priority patent/GB9705619D0/en
Priority claimed from GBGB9726695.1A external-priority patent/GB9726695D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BR9809047A publication Critical patent/BR9809047A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

''DERIVADOS DE ISOQUINOLINA SUBSTITUìDA E O USO DOS MESMOS COMO ANTICONVULSIVANTES'' São proporcionados compostos de fórmula (I) e sais farmaceuticamente aceitáveis dos mesmos; onde Q é um anel arila ou heteroarila monocíclico ou bicíclico, R^ 1^ é hidrogênio, alquila C~ 1-6~ (opcionalmente substituído por hidróxi ou - alcóxi C~ 1-4~), alquenila C~ 1-6~, alquinila C~ 1-6~, alquilCO C~ 1-6~-, formila, CF~ 3~CO- ou C~ 1-6~ alquilSO~ 2~-, R^ 2^ é hidrogênio, hidróxi, ou cerca de três substituintes selecionados a partir de halogênio, NO~ 2~, CN, N~ 3~, CF~ 3~S-, CF~ 3~CO-, trifluorometildiazirinila, alquila C~ 1-6~, alquenila C~ 1-6~, alquinila C~ 1-6~, perfluoroalquila C~ 1-6~, cicloalquila C~ 3-6~, cicloalquila C~ 3-6~- alquila C~ 1-4~-, alquilO C~ 1-6~ -, alquilCO C~ 1-6~ -, ciloclaquilo C~ 3-6~-, cicloalquilCO C~ 3-6~-, cicloalquila C~ 3-6~- alquilO C~ 1-4~-, cicloalquila C~ 3-6~- alquilCO C~ 1-4~-, acetóxi, fenila, fenóxi, benzilóxi, benzoila, fenil-C~ 1-4~ alquila-, alquilS C~ 1-6~ -, alquilSO~ 2~ C~ 1-6~ -, (alquila C~ 1-4~)~ 2~NSO~ 2~-, (alquila C~ 1-4~)NHSO~ 2~-, (alquila C~ 1-4~)~ 2~NCO-, (alquila C~ 1-4)NHCO- ou CONH~ 2~; ou -NR^ 3^R^ 4^ onde R^ 3^ é hidrogênio ou alquila C~ 1-4~, e R^ 4^ é hidrogênio, alquila C~ 1-4~, formila, -CO~ 2~ alquila C~ 1-4~ ou -CO alquila C~ 1-4~; ou dois grupos R^ 2^ juntos formam um anel carbocíclico que é saturado ou insaturado e substituído ou insubstituído por -OH ou W; e X is hidrogênio, halogênio, C~ 1-6~ alcóxi, C~ 1-6~ alquila, amina ou trifluoroacetilamina; mas quando X is hidrogênio excluindo-se os compostos nos quais R^ 2^ é 2-alcóxi e quando X is halogênio excluindo-se os compostos N- (7-iodo-2-metil-1,2,3,4-tetrahidroisoquinolin-5-il) -5-benzoil-2-metóxibenzamida, N- (7-iodo-1,2,3,4-tetrahidroisoquinolin-5-il) -5-benzoil-2-metóxibenzamida, N- (5-iodo-1,2,3,4-tetrahi-droisoquinolin-7-il) -5-benzoil-2-metóxibenzamida, N- (5-iodo-1,2,3,4-tetrahidroisoquinolin-7-il) -2-metóxi-4-trifluorometildiarizinilbenzamida, N- (5-iodo-1,2,3,4-tetrahidroisoquinolin-7-il) -2-metóxi-5-trifluorometildiarizinibenzamida, N- (7-iodo-1,2,3,4-tetrahidroisoquinolin-5-il) -2-metóxi-5-trifluorometildiarizinilbenzamida e N- (8-fluoro-2-metil-1,2,3,4-tetrahidroisoquinolin-5-il) -4-t-butil-2-metóxibenzamida, são úteis inter alia, no tratamento e na profilaxia da epilepsia.
BR9809047-0A 1997-03-18 1998-03-16 Derivados de isoquinolina substituìda e o uso dos mesmos como anticonvulsivantes BR9809047A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9705619.6A GB9705619D0 (en) 1997-03-18 1997-03-18 Novel compounds
GBGB9726695.1A GB9726695D0 (en) 1997-12-17 1997-12-17 Novel compounds
PCT/GB1998/000782 WO1998041508A1 (en) 1997-03-18 1998-03-16 Substituted isoquinoline derivatives and their use as anticonvulsants

Publications (1)

Publication Number Publication Date
BR9809047A true BR9809047A (pt) 2000-08-01

Family

ID=26311215

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809047-0A BR9809047A (pt) 1997-03-18 1998-03-16 Derivados de isoquinolina substituìda e o uso dos mesmos como anticonvulsivantes

Country Status (16)

Country Link
EP (1) EP0968190A1 (pt)
JP (1) JP3690423B2 (pt)
KR (1) KR100568654B1 (pt)
CN (1) CN1183116C (pt)
AR (1) AR012092A1 (pt)
AU (1) AU737955B2 (pt)
BR (1) BR9809047A (pt)
CA (1) CA2284218A1 (pt)
CO (1) CO4950553A1 (pt)
IL (1) IL131756A0 (pt)
NO (1) NO314081B1 (pt)
NZ (1) NZ337424A (pt)
PL (1) PL192116B1 (pt)
TR (1) TR199902283T2 (pt)
TW (1) TW555694B (pt)
WO (1) WO1998041508A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726695D0 (en) * 1997-12-17 1998-02-18 Smithkline Beecham Plc Novel compounds
WO1999021836A1 (en) * 1997-10-24 1999-05-06 Smithkline Beecham Plc Substituted isoquinoline derivatives and their use as anticonvulsants
GB9817424D0 (en) 1998-08-11 1998-10-07 Smithkline Beecham Plc Novel compounds
AU1909700A (en) * 1998-12-03 2000-06-19 Ortho-Mcneil Pharmaceutical, Inc. Topiramate and related derivatives for treating Schizophrenia
ATE306481T1 (de) * 1999-05-12 2005-10-15 Ortho Mcneil Pharm Inc Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
FR2795724B1 (fr) * 1999-07-02 2002-12-13 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
GB9915589D0 (en) * 1999-07-02 1999-09-01 Smithkline Beecham Plc Novel compounds
ES2316777T3 (es) * 2002-02-15 2009-04-16 Glaxo Group Limited Moduladores de receptores vainilloides.
GB0210762D0 (en) * 2002-05-10 2002-06-19 Glaxo Group Ltd Compounds
AU2003249534A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
GB0226724D0 (en) * 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
KR20060027338A (ko) 2003-06-12 2006-03-27 아스텔라스세이야쿠 가부시키가이샤 벤즈 아미드 유도체 또는 그 염
GB2413129A (en) * 2003-10-07 2005-10-19 Renovis Inc Aromatic amide compounds as ion channel ligands and uses thereof
US7338950B2 (en) 2003-10-07 2008-03-04 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
US20050165028A1 (en) * 2004-01-23 2005-07-28 Norman Mark H. Vanilloid receptor ligands and their use in treatments
JP2008513426A (ja) * 2004-09-20 2008-05-01 バイオリポックス エービー 炎症の治療に有用なピラゾール化合物
SE0403117D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab New compounds 1
DK2046787T3 (da) 2006-08-01 2011-07-18 Glaxo Group Ltd Pyrazolo[3,4-B]pyridin-forbindelser, og deres anvendelse som PDE4-inhibitorer
CN106608901B (zh) * 2015-10-22 2020-10-16 彭莉 二羟基二甲基四氢异喹啉-3-甲酰-Lys(Lys-Ala),其合成,活性及应用
CN111138359A (zh) * 2020-01-19 2020-05-12 浙江农林大学暨阳学院 制备3-羰基-4-叠氮基-n-苯磺酰基-1,2,3,4-四氢异喹啉类化合物的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022900A (en) * 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
EP0906283A1 (en) * 1996-06-17 1999-04-07 Smithkline Beecham Plc Substituted benzamide derivatives and their use as anticonvulsants

Also Published As

Publication number Publication date
TR199902283T2 (xx) 1999-12-21
CN1255124A (zh) 2000-05-31
AU737955B2 (en) 2001-09-06
JP3690423B2 (ja) 2005-08-31
NZ337424A (en) 2001-08-31
PL335676A1 (en) 2000-05-08
PL192116B1 (pl) 2006-08-31
EP0968190A1 (en) 2000-01-05
JP2001515504A (ja) 2001-09-18
CO4950553A1 (es) 2000-09-01
KR100568654B1 (ko) 2006-04-07
AU6412898A (en) 1998-10-12
TW555694B (en) 2003-10-01
NO994510D0 (no) 1999-09-17
NO994510L (no) 1999-09-17
WO1998041508A1 (en) 1998-09-24
NO314081B1 (no) 2003-01-27
IL131756A0 (en) 2001-03-19
AR012092A1 (es) 2000-09-27
CN1183116C (zh) 2005-01-05
KR20000076342A (ko) 2000-12-26
CA2284218A1 (en) 1998-09-24

Similar Documents

Publication Publication Date Title
BR9809047A (pt) Derivados de isoquinolina substituìda e o uso dos mesmos como anticonvulsivantes
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
DE69823843D1 (de) Benzimidazolinone, benzoxazolinone, benzopiperazinone, indanone und deren derivate als faktor xa inhibitoren
ATE171447T1 (de) Benzimidazole derivate
ATE360631T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
ATE302775T1 (de) Carbolinderivate
TR200102839T2 (tr) LH agonistleri olarak faydalı bisiklik heteroaromatik bileşikler.
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
ATE405266T1 (de) Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa
DE69530690D1 (de) Benzoheterocyclische derivate verwendbar als vasopressin- oder oxytocin-modulatoren
BR0205829A (pt) Novas aminas como ligantes dos receptores de histamina-3 e suas aplicações terapêuticas
BR0002515A (pt) Derivados de 4-arilpiperidina para o tratamento do prurido
AR050598A2 (es) Composicion funguicida sinergica, procedimiento para combatir hongos nocivos y uso de los compuestos que integran dicha composicion para la preparacion de dichas mezclas sinergicas
ATE346067T1 (de) Carbolinderivate
ATE332903T1 (de) Kondensierte pyridoindolderivate
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
ATE300543T1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
BR0315777A (pt) Uso de derivados de piperazina como antagonistas ccr1
BR0208205A (pt) Derivados de benzimidazol moduladores de receptores de quimocinas
DE60121587D1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
RS52427B (en) ANTIBIOTIC 107891, ITS FACTORS, PHARMACEUTICALALLY ACCEPTABLE SALTS AND MIXTURES, AND THEIR USE
ATE302776T1 (de) Kondensierte pyridoindolderivate
BR9913183A (pt) Composto, uso do mesmo, processo para prepará-lo, processo para tratar um indivìduo humano ou animal, e, composição farmacêutica
DK1197223T3 (da) Farmaceutisk præparat til forebyggelse, behandling eller udviklingsinhibition af simpel retinopati eller præproliferativ retinopati
ATE337320T1 (de) Indolderivate als pde5-inhibitoren

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements